Copyright Reports & Markets. All rights reserved.

Global Gene Modifying Immunotherapy for Blood Cancer Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 CAR T-cell Therapy
      • 1.4.3 TCR T-cell Therapy
    • 1.5 Market by Application
      • 1.5.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2025)
      • 1.5.2 Acute Lymphocytic Leukemia
      • 1.5.3 Chronic Lymphocytic Leukemia
      • 1.5.4 B Cell Lymphoma
      • 1.5.5 Multiple Myeloma
      • 1.5.6 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size
    • 2.2 Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Regions
      • 2.2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions (2019-2025)
      • 2.2.2 Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by by Players
      • 3.1.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue by by Players (2014-2019)
      • 3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
    • 3.2 Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Area Served
    • 3.3 Key Players Gene Modifying Immunotherapy for Blood Cancer Product/Solution/Service
    • 3.4 Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2014-2019)
    • 4.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
    • 5.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in North America
    • 5.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
    • 5.4 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

    6 Europe

    • 6.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
    • 6.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Europe
    • 6.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
    • 6.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

    7 China

    • 7.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
    • 7.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in China
    • 7.3 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
    • 7.4 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

    8 Japan

    • 8.1 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
    • 8.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Japan
    • 8.3 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
    • 8.4 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
    • 9.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Southeast Asia
    • 9.3 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
    • 9.4 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

    10 India

    • 10.1 India Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
    • 10.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in India
    • 10.3 India Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
    • 10.4 India Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
    • 11.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Central & South America
    • 11.3 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
    • 11.4 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

    12 International Players Profiles

    • 12.1 Novartis
      • 12.1.1 Novartis Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
      • 12.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019))
      • 12.1.5 Novartis Recent Development
    • 12.2 Kite Pharma
      • 12.2.1 Kite Pharma Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
      • 12.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
      • 12.2.5 Kite Pharma Recent Development
    • 12.3 Juno Therapeutics
      • 12.3.1 Juno Therapeutics Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
      • 12.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
      • 12.3.5 Juno Therapeutics Recent Development
    • 12.4 Cellectis
      • 12.4.1 Cellectis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
      • 12.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
      • 12.4.5 Cellectis Recent Development
    • 12.5 Ziopharm Oncology
      • 12.5.1 Ziopharm Oncology Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
      • 12.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
      • 12.5.5 Ziopharm Oncology Recent Development
    • 12.6 Celyad
      • 12.6.1 Celyad Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
      • 12.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
      • 12.6.5 Celyad Recent Development
    • 12.7 Bluebird Bio
      • 12.7.1 Bluebird Bio Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
      • 12.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
      • 12.7.5 Bluebird Bio Recent Development
    • 12.8 Bellicum Pharmaceuticals
      • 12.8.1 Bellicum Pharmaceuticals Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
      • 12.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
      • 12.8.5 Bellicum Pharmaceuticals Recent Development
    • 12.9 Mustang Bio
      • 12.9.1 Mustang Bio Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
      • 12.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
      • 12.9.5 Mustang Bio Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      This report focuses on the global Gene Modifying Immunotherapy for Blood Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Modifying Immunotherapy for Blood Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Novartis
      Kite Pharma
      Juno Therapeutics
      Cellectis
      Ziopharm Oncology
      Celyad
      Bluebird Bio
      Bellicum Pharmaceuticals
      Mustang Bio

      Market segment by Type, the product can be split into
      CAR T-cell Therapy
      TCR T-cell Therapy

      Market segment by Application, split into
      Acute Lymphocytic Leukemia
      Chronic Lymphocytic Leukemia
      B Cell Lymphoma
      Multiple Myeloma
      Other

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Gene Modifying Immunotherapy for Blood Cancer status, future forecast, growth opportunity, key market and key players.
      To present the Gene Modifying Immunotherapy for Blood Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Gene Modifying Immunotherapy for Blood Cancer are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now